Pharmacokinetics and Administration Regimens of Vancomycin in Neonates, Infants and Children

[1]  J. Dipiro,et al.  Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation , 1996, Antimicrobial agents and chemotherapy.

[2]  J. Scribante,et al.  Changes in Vancomycin Pharmacokinetics in Critically Ill Infants , 1995, Anaesthesia and intensive care.

[3]  C. Cabellos,et al.  Influence of dexamethasone on efficacy of ceftriaxone and vancomycin therapy in experimental pneumococcal meningitis , 1995, Antimicrobial agents and chemotherapy.

[4]  J. Bradley,et al.  Bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with acute bacterial meningitis , 1995, Antimicrobial agents and chemotherapy.

[5]  D. Oriot,et al.  Cardiac arrest associated with vancomycin in a neonate , 2008 .

[6]  M. Levine,et al.  Vancomycin Pharmacokinetics and Dosing in Premature Neonates , 1995, Therapeutic drug monitoring.

[7]  D. Chang.  Influence of malignancy on the pharmacokinetics of vancomycin in infants and children. , 1995, The Pediatric infectious disease journal.

[8]  N. Saunders.  Vancomycin administration and monitoring reappraisal. , 1995, The Journal of antimicrobial chemotherapy.

[9]  K. Rodvold,et al.  Bayesian Forecasting of Serum Vancomycin Concentrations in Neonates and Infants , 1995, Therapeutic drug monitoring.

[10]  W. Leader,et al.  Pharmacokinetic Optimisation of Vancomycin Therapy , 1995, Clinical pharmacokinetics.

[11]  R. Pryka.  Vancomycin Serum Concentration Monitoring: A Continued Debate , 1994, The Annals of pharmacotherapy.

[12]  M. Malogolowkin,et al.  A prospective study of vancomycin pharmacokinetics and dosage requirements in pediatric cancer patients. , 1994, The Pediatric infectious disease journal.

[13]  R. Brundage,et al.  Population pharmacokinetics of vancomycin in neonates , 1994, Clinical pharmacology and therapeutics.

[14]  K. Olsen,et al.  Effect of dexamethasone on therapy of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis , 1994, Antimicrobial Agents and Chemotherapy.

[15]  F. Boucher,et al.  Possible Red-Man Syndrome Associated with Systemic Absorption of Oral Vancomycin in a Child with Normal Renal Function , 1994, The Annals of pharmacotherapy.

[16]  Wandstrat Tl,et al.  Vancomycin dosing in neonatal patients: the controversy continues. , 1994 .

[17]  R. Moellering.  Monitoring serum vancomycin levels: climbing the mountain because it is there? , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  P. Lietman,et al.  Serum vancomycin concentrations: reappraisal of their clinical value. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  G. Koren,et al.  Safety of vancomycin with or without gentamicin in neonates. , 1993, Neonatal network : NN.

[20]  C. C. Patrick,et al.  Clinical and microbiologic aspects of Staphylococcus haemolyticus infections , 1993, The Pediatric Infectious Disease Journal.

[21]  M. Gabriel,et al.  Vancomycin dosing for neonates. , 1993, The Pediatric Infectious Disease Journal.

[22]  G. Koren,et al.  Preliminary Studies of the Effects of Extracorporeal Membrane Oxygenator on the Disposition of Common Pediatric Drugs , 1993, Therapeutic drug monitoring.

[23]  J. Hatton,et al.  Vancomycin Administration into the Cerebrospinal Fluid: A Review , 1993, The Annals of pharmacotherapy.

[24]  John E. Murphy,et al.  Vancomycin Pharmacokinetics in Neonates and Infants: A Retrospective Evaluation , 1993, The Annals of pharmacotherapy.

[25]  P. D. del Nido,et al.  Pharmacokinetics of intravenous vancomycin in pediatric cardiopulmonary bypass surgery. , 1993, The Pediatric infectious disease journal.

[26]  Jarrett Rv,et al.  Individualized pharmacokinetic profiles to compute vancomycin dosage and dosing interval in preterm infants , 1993 .

[27]  M. Reed,et al.  Vancomycin and Tobramycin Clearance in an Infant during Continuous Hemofiltration , 1993, The Annals of pharmacotherapy.

[28]  G. Sharpe,et al.  Overestimation of serum vancomycin concentrations using a fluorescence polarization immunoassay (Tdx) in preterm neonates. , 1993, Developmental Pharmacology and Therapeutics.

[29]  K. Kulig,et al.  Exchange transfusion and multidose activated charcoal following vancomycin overdose. , 1992, Journal of toxicology. Clinical toxicology.

[30]  L. Gortner,et al.  Prophylactic low-dose vancomycin treatment in very-low-birth-weight infants. , 1992, Developmental pharmacology and therapeutics.

[31]  J. Becerra,et al.  Morbidity estimates of conditions originating in the perinatal period: United States, 1986 through 1987. , 1991, Pediatrics.

[32]  K. Rodvold,et al.  An Updated Comparison of Drug Dosing Methods , 1991, Clinical pharmacokinetics.

[33]  J D Horbar,et al.  Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Network. , 1991, Pediatrics.

[34]  S. Hall,et al.  Coagulase-negative staphylococcal infections in neonates. , 1991, The Pediatric infectious disease journal.

[35]  M. Hu,et al.  Measurement of Vancomycin in Renally Impaired Patient Samples Using a New High‐Performance Liquid Chromatography Method with Vitamin B12 Internal Standard: Comparison of High‐Performance Liquid Chromatography, Emit, and Fluorescence Polarization Immunoassay Methods , 1990, Therapeutic drug monitoring.

[36]  L. Dupuis,et al.  Vancomycin-induced red man syndrome. , 1990, Pediatrics.

[37]  C. C. Patrick.  Coagulase-negative staphylococci: pathogens with increasing clinical significance. , 1990, The Journal of pediatrics.

[38]  S. Kaplan,et al.  Ventricular fluid concentrations of vancomycin in children after intravenous and intraventricular administration. , 1990, The Pediatric infectious disease journal.

[39]  M. Nahata,et al.  Pharmacokinetics and cerebrospinal fluid (CSF) concentrations of vancomycin in pediatric patients undergoing CSF shunt placement. , 1990, Chemotherapy.

[40]  R. Nelson,et al.  Vancomycin pharmacokinetics in infants undergoing extracorporeal membrane oxygenation. , 1990, Clinical pharmacy.

[41]  K. Chan,et al.  Potential problem with fluorescence polarization immunoassay cross-reactivity to vancomycin degradation product CDP-1: its detection in sera of renally impaired patients. , 1989, Therapeutic drug monitoring.

[42]  M. Winter,et al.  Aminoglycoside and vancomycin pharmacokinetic monitoring in pediatric patients. , 1989, American journal of hospital pharmacy.

[43]  G. Koren,et al.  Vancomycin pharmacokinetics in very low birth weight neonates. , 1989, The Pediatric infectious disease journal.

[44]  E. Sumner,et al.  Perioperative complications following the use of vancomycin in children: a report of two cases. , 1989, British journal of anaesthesia.

[45]  D. Baker,et al.  Vancomycin does not enhance amikacin-induced tubular nephrotoxicity in children. , 1989, The Pediatric infectious disease journal.

[46]  H. Modanlou,et al.  Vancomycin pharmacokinetics in infants: relationship to postconceptional age and serum creatinine. , 1989, Developmental pharmacology and therapeutics.

[47]  R. Finch,et al.  The in-vitro degradation at 37°C of vancomycin in serum, CAPD fluid and phosphate-buffered saline , 1988 .

[48]  D. Harvey,et al.  Antibiotic therapy of the newborn. , 1988, Clinics of Perinatology.

[49]  R. Bayston,et al.  Intraventricular vancomycin in the treatment of ventriculitis associated with cerebrospinal fluid shunting and drainage. , 1987, Journal of neurology, neurosurgery, and psychiatry.

[50]  R. Kliegman,et al.  The Clinical Pharmacology of Vancomycin in Seriously Ill Preterm Infants , 1987, Pediatric Research.

[51]  C. Raftopoulos,et al.  Intraventricular vancomycin in CSF shunt infections. , 1987, Neurosurgery.

[52]  G. Morse,et al.  Overestimation of Vancomycin Concentrations Utilizing Fluorescence Polarization Immunoassay in Patients on Peritoneal Dialysis , 1987, Therapeutic drug monitoring.

[53]  G. Koren,et al.  Vancomycin dosing in preterm infants: prospective verification of new recommendations. , 1987, The Journal of pediatrics.

[54]  R. Mclaurin,et al.  Treatment of infections of cerebrospinal fluid shunts. , 1987, Reviews of infectious diseases.

[55]  G. Koren,et al.  Vancomycin pharmacokinetics and dose recommendations for preterm infants , 1987, Antimicrobial Agents and Chemotherapy.

[56]  R. Reichley,et al.  Vancomycin Pharmacokinetics in Neonates-Reply , 1986 .

[57]  P. Gal,et al.  Vancomycin pharmacokinetics in neonates. , 1986, American journal of diseases of children.

[58]  R. Polin,et al.  Vancomycin pharmacokinetics in infants: relationships to indices of maturation. , 1986, Pediatric infectious disease.

[59]  R. Reichley,et al.  Vancomycin pharmacokinetics in small, seriously ill infants. , 1986, American journal of diseases of children.

[60]  M. Fisher,et al.  Intraventricular vancomycin: observations of tolerance and pharmacokinetics in two infants with ventricular shunt infections , 1986, Pediatric infectious disease.

[61]  R. Dean,et al.  Vancomycin/aminoglycoside nephrotoxicity. , 1985, The Journal of pediatrics.

[62]  S. Kaplan,et al.  Vancomycin pharmacokinetics in premature infants. , 1985, Pediatric pharmacology.

[63]  J. Mayhew,et al.  Cardiac arrest following administration of vancomycin , 1985, Canadian Anaesthetists' Society journal.

[64]  J. Rotschafer,et al.  Increased vancomycin dosage requirements in young burn patients , 1984 .

[65]  G. Mccracken,et al.  Nephrotoxicity associated with vancomycin-aminoglycoside therapy in four children. , 1984, The Journal of pediatrics.

[66]  L. Scherer,et al.  Staphylococcus epidermidis sepsis in pediatric patients: clinical and therapeutic considerations. , 1984, Journal of pediatric surgery.

[67]  D. Armstrong,et al.  Staphylococcus epidermidis septicemia in children with leukemia and lymphoma. , 1984, American journal of diseases of children.

[68]  D. Powell,et al.  Effect of gestational age and birth weight on tobramycin kinetics in newborn infants. , 1984, Journal of Antimicrobial Chemotherapy.

[69]  G. Alpert,et al.  Vancomycin dosage in pediatrics reconsidered. , 1984, American journal of diseases of children.

[70]  C. Ray,et al.  Vancomycin in perspective. , 1984, American journal of diseases of children.

[71]  E. Kaplan.  Vancomycin in infants and children: a review of pharmacology and indications for therapy and prophylaxis. , 1984, The Journal of antimicrobial chemotherapy.

[72]  F. Sklar,et al.  Adverse reactions to vancomycin used as prophylaxis for CSF shunt procedures. , 1984, American journal of diseases of children.

[73]  Arroyo Jc,et al.  Accumulation of vancomycin after intraventricular infusions. , 1983 .

[74]  C. Harris,et al.  VANCOMYCIN: STRUCTURE AND TRANSFORMATION TO CDP-I , 1983 .

[75]  P. Gilligan,et al.  Absorption of oral vancomycin - possible associated toxicity. , 1983, The International journal of pediatric nephrology.

[76]  C. Baker,et al.  Median sternotomy wound infections in children , 1983, Pediatric infectious disease.

[77]  F. Daschner,et al.  Analysis of bacterial infections in a neonatal intensive care unit. , 1982, The Journal of hospital infection.

[78]  G. Mccracken,et al.  Pharmacology and Efficacy of Vancomycin for Staphylococcal Infections in Children , 1981 .

[79]  P. A. Davies,et al.  Changing blood culture isolates in a referral neonatal intensive care unit. , 1981, Archives of disease in childhood.

[80]  R. B. Johnston.  The host response to invasion by Streptococcus pneumoniae: protection and the pathogenesis to tissue damage. , 1981, Reviews of infectious diseases.

[81]  G. Mccracken,et al.  Clinical pharmacology and efficacy of vancomycin in pediatric patients. , 1980, The Journal of pediatrics.

[82]  R. Spears,et al.  The use of vancomycin in pediatrics. , 1959, Antibiotics annual.